JAMA:二甲双胍在2型糖尿病和肾脏疾病中的应用

2014-12-29 angletears 译 MedSci原创

普遍认为,二甲双胍是首选的治疗2型糖尿病的口服降糖药物。但是,由于其有导致乳酸酸中毒的风险,一直禁用于合并严重肾脏疾病的糖尿病患者。最近发表在JAMA上一篇文章,系统的评价合并严重肾脏疾病的糖尿病患者使用二甲双胍,出现乳酸酸中毒的风险。文章搜索了MEDLINE和 Cochrane两个数据库中,从1950年到2014年6月,所有关于二甲双胍,肾脏疾病,乳酸酸中毒的英文文献。排除了综述、快报、评论、案

普遍认为,二甲双胍是首选的治疗2型糖尿病的口服降糖药物。但是,由于其有导致乳酸酸中毒的风险,一直禁用于合并严重肾脏疾病的糖尿病患者。最近发表在JAMA上一篇文章,系统的评价合并严重肾脏疾病的糖尿病患者使用二甲双胍,出现乳酸酸中毒的风险。


文章搜索了MEDLINE和 Cochrane两个数据库中,从1950年到2014年6月,所有关于二甲双胍,肾脏疾病,乳酸酸中毒的英文文献。排除了综述、快报、评论、案例报告、小案例研究、手稿等没有直接涉及这个主题的、或者符合其他排除标准的文章。在原始的818篇文献中,纳入65篇进行分析,其中包括药代动力学/新陈代谢的研究,大型的案例分析,回顾性研究,Meta分析及临床试验。

结果显示:虽然二甲双胍是通过肾脏清除的,但是在合并轻度到中度的慢性肾脏疾病(估算肾小球率过滤是30-60ml/min每1.73平方米)的患者中,使用治疗剂量二甲双胍,乳酸浓度并没有显著的增加。合并肾脏疾病的糖尿病患者使用二甲双胍的乳酸酸中毒的总发生率,在不同研究中,从3/10万人年到10/10万人年,通常不能辨别出和总的糖尿病人群中乳酸酸中毒的发生率有何区别。关于合并严重肾脏疾病的患者使用二甲双胍可以增加乳酸酸中毒的风险的数据很有限,而且没有随机对照试验来检测合并严重肾脏疾病的患者使用二甲双胍的安全性。基于人群的研究证明,二甲双胍的使用可以与现行的指南相反,因为大多数的研究结果表明,虽然有超过1/4的T2DM患者有合并肾脏疾病的风险,但是,乳酸酸中毒的增长率与肾脏疾病的风险无关。而且,观察结果显示二甲双胍对大血管并发症有潜在的保护作用,甚至在普遍认为有肾脏疾病禁忌症的患者中也是如此。

文章得出结论:现有证据支持可以在合并轻度到中度慢性肾脏疾病(使用估算的肾小球滤过率定义)的糖尿病患者中,通过减少药物剂量和严密监测肾功能,慎用二甲双胍。

原始出处:

Inzucchi SE1, Lipska KJ1, Mayo H2, Bailey CJ3, McGuire DK4.Metformin in patients with type 2 diabetes and kidney disease: a systematic review.JAMA. 2014 Dec 24;312(24):2668-75. doi: 10.1001/jama.2014.15298.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=33921, encodeId=986b33921d9, content=二甲双胍很火啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Fri Jul 31 17:12:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20267, encodeId=c2242026e25, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14335, encodeId=e0321433560, content=密切关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:31:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14334, encodeId=7bdc1433483, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:28:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13944, encodeId=e02213944bd, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:28:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-07-31 sundong

    二甲双胍很火啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=33921, encodeId=986b33921d9, content=二甲双胍很火啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Fri Jul 31 17:12:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20267, encodeId=c2242026e25, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14335, encodeId=e0321433560, content=密切关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:31:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14334, encodeId=7bdc1433483, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:28:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13944, encodeId=e02213944bd, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:28:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-04-11 x35042875

    AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=33921, encodeId=986b33921d9, content=二甲双胍很火啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Fri Jul 31 17:12:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20267, encodeId=c2242026e25, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14335, encodeId=e0321433560, content=密切关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:31:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14334, encodeId=7bdc1433483, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:28:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13944, encodeId=e02213944bd, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:28:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-01-14 gongzuozhong

    密切关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=33921, encodeId=986b33921d9, content=二甲双胍很火啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Fri Jul 31 17:12:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20267, encodeId=c2242026e25, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14335, encodeId=e0321433560, content=密切关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:31:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14334, encodeId=7bdc1433483, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:28:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13944, encodeId=e02213944bd, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:28:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-01-14 gongzuozhong

    不错不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=33921, encodeId=986b33921d9, content=二甲双胍很火啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Fri Jul 31 17:12:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20267, encodeId=c2242026e25, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:26:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14335, encodeId=e0321433560, content=密切关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:31:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14334, encodeId=7bdc1433483, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Jan 14 17:28:00 CST 2015, time=2015-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13944, encodeId=e02213944bd, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:28:00 CST 2015, time=2015-01-10, status=1, ipAttribution=)]
    2015-01-10 zczcz6655

    新的观点新的想法

    0

相关资讯

FDA批准坎格列净/二甲双胍固定复方制剂上市

近日,美国食品与药物管理局(FDA)批准了钠葡萄糖共同转运蛋白2(SGLT2)抑制剂坎格列净(canagliflozin)与二甲双胍的固定复方制剂用于治疗成人2型糖尿病。该药名为Invokamet,包括50 或150 mg 坎格列净或500或1000 mg 二甲双胍的片剂,推荐剂量为每日两次,是美国市场上的首个坎格列净与二甲双胍的固定复方制剂。 今年的早些时候,该产品遭到FDA的拒绝,并

EASD 2014:二甲双胍联合SAXA和DAPA改善血糖更佳

欧洲糖尿病研究学会(EASD2014)年会的一项报告表明,在二甲双胍控制不佳的2型糖尿病患者中,联合加用SAXAgliptin(SAXA)和DAPAgliflozin(DAPA)可更大程度地改善血糖控制,有超过40%血糖控制不佳的2型糖尿病患者在接受上述治疗后实现了A1C<7%的目标,并且低血糖风险极低。 此项为期24周的多中心随机双盲研究共纳入534例8.0%≤A1C≤12.0%

Diabetes Obes Metabo:二甲双胍对肥胖儿童的影响

根据公布在Diabetes, Obesity and Metabolism杂志上一则研究提示,对于肥胖儿童,二甲双胍似乎可以降低饥饿感和增加饱腹感觉。 美国国立卫生研究院Mopelola A. Adeyemo和他的同事对年龄在6至12岁的100名肥胖高胰岛素血症儿童,进行了一项为期6个月的随机、双盲、安慰剂对照试验,以评估二甲双胍对体重和能量平衡的影响,共84名儿童数据可用(45名二甲双胍治

Eur J Cancer:二甲双胍能降低2型糖尿病患者前列腺癌风险

二甲双胍是最常用的口服降糖药,目前已成为公认的“全球控制糖尿病的核心药物”,是“糖尿病治疗中的基石”。除了抗糖尿病作用之外,也有研究报道二甲双胍还可通过一系列不同的机制来阻碍肿瘤的进展和肿瘤的形成。9月发表在Eur J Cancer的一项来自台湾的population base的研究表明,二甲双胍能降低2型糖尿病患者前列腺癌风险。 前列腺癌是男性最常见的恶性

CSE 2014:二甲双胍临床应用中国专家共识发表

二甲双胍自1957年问世,应用于临床已有50多年的历史,是当前全球应用最广泛的口服降糖药之一。近年来,虽然有多个新型降糖药物上市,但二甲双胍仍是在全球使用量迅速增加的经典口服降糖药物。二甲双胍具有良好的单药/联合治疗的疗效和安全性证据,以及良好的卫生经济学效益证据。无论对于血糖控制,还是糖尿病心血管并发症的预防,二甲双胍都有明确的临床证据。因此,二甲双胍已经成为全球控制糖尿病的核心药物。然而,在临

Diabetes Obes Metab:2型糖尿病一线单药治疗二甲双胍的死亡率低于磺脲类

2型糖尿病患者的治疗,胰岛素的作用效果较差,可以通过某些口服药物刺激体内胰岛素的分泌,二甲双胍和磺脲是两大选择。2014年10月发表在Diabetes Obes Metab.的一项英国研究,对一线单药治疗使用磺脲或二甲双胍患者全因死亡和主要不良心血管事件(MACE)的风险进行了评估,结果发现2型糖尿病患者一线单药治疗磺脲的死亡率高于二甲双胍。 数据来源于临床实践研究数据链(C